Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00210782
Status:
COMPLETED
Last Update Posted:
2011-06-10
First Post:
2005-09-13
Brief Title:
A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment
Sponsor:
Johnson Johnson Pharmaceutical Research Development LLC
Organization:
Johnson Johnson Pharmaceutical Research Development LLC
Study Overview
Official Title:
A Double-blind Trial Comparing the Efficacy Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effectiveness and safety of two treatment regimens topiramate as compared to phenytoin in preventing seizures in patients with new-onset epilepsy who require rapid initiation of antiepileptic drug therapy Reasons for requiring rapid initiation of treatment rather than slowly increasing an antiepileptic drug to an effective dose may include severe or frequent seizures or high risk to the patient of recurrent seizures
Detailed Description:
In this study patients who have recently been diagnosed with epilepsy and who require rapid initiation of treatment will be randomized to receive either phenytoin or topiramate Patients have an equal chance of receiving either medication Phenytoin and topiramate have been approved by the FDA for treatment of epilepsy The first phase of this study lasting 28 days is double-blind meaning that neither the patient or the physician know which medication the patient is receiving Phenytoin will be used according to the dosing recommendation in the package insert Patients randomized into the phenytoin arm of this study will receive a dose on day 1 of 1000mg phenytoin given in 3 divided doses an initiation dose recommended in the product labeling This will be followed by 300mg of phenytoin on each subsequent day Patients randomized into the topiramate arm of this study will receive 100mg of topiramate on day 1 and then continue to receive 100mg on each subsequent day This is a relatively rapid initiation schedule of topiramate but it is anticipated that it will be well tolerated and represents an appropriate regimen for comparison to patients in the phenytoin arm of the study Patients will be carefully monitored for primary generalized tonic clonic seizures or complex partial onset seizures two distinct epileptic seizure types during the 28-day double-blind evaluation period of the trial If a patient experiences a seizure during this 28 day period they will either be taken out of the study or be offered the option to receive a higher dose of topiramate in an open-label fashion Open-label means that the patient and the physician will know what medication and what dose of the medication the patient is taking All patients who do not experience a seizure during the 28 day period will be offered to receive open-label topiramate for an additional 12 weeks The study hypothesis is that the proportion of patients who do not have a seizure within the 28 day double blind phase of the study will not differ between the 2 treatment groups Topiramate 100 milligrams a day by mouth for 4 weeks phenytoin 1000 milligrams to start decreased to 300 milligrams a day by mouth for 4 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None